EVOLUS INC (EOLS) Fundamental Analysis & Valuation

NASDAQ:EOLS • US30052C1071

5.79 USD
+0.2 (+3.58%)
Last: Mar 5, 2026, 02:52 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This EOLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall EOLS gets a fundamental rating of 2 out of 10. We evaluated EOLS against 193 industry peers in the Pharmaceuticals industry. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative. EOLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. EOLS Profitability Analysis

1.1 Basic Checks

  • In the past year EOLS has reported negative net income.
  • EOLS had a negative operating cash flow in the past year.
  • In the past 5 years EOLS always reported negative net income.
  • In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • EOLS has a Return On Assets of -26.74%. This is comparable to the rest of the industry: EOLS outperforms 56.48% of its industry peers.
Industry RankSector Rank
ROA -26.74%
ROE N/A
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • With a decent Gross Margin value of 65.83%, EOLS is doing good in the industry, outperforming 75.13% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EOLS has declined.
  • EOLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. EOLS Health Analysis

2.1 Basic Checks

  • EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for EOLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • EOLS has an Altman-Z score of -2.24. This is a bad value and indicates that EOLS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of EOLS (-2.24) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.24
ROIC/WACCN/A
WACC10.71%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • EOLS has a Current Ratio of 2.02. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of EOLS (2.02) is worse than 60.10% of its industry peers.
  • EOLS has a Quick Ratio of 1.53. This is a normal value and indicates that EOLS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.53, EOLS is not doing good in the industry: 60.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.53
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. EOLS Growth Analysis

3.1 Past

  • The earnings per share for EOLS have decreased strongly by -72.00% in the last year.
EPS 1Y (TTM)-72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.38%

3.2 Future

  • Based on estimates for the next years, EOLS will show a very strong growth in Earnings Per Share. The EPS will grow by 49.20% on average per year.
  • Based on estimates for the next years, EOLS will show a quite strong growth in Revenue. The Revenue will grow by 16.64% on average per year.
EPS Next Y91.3%
EPS Next 2Y63.8%
EPS Next 3Y86.6%
EPS Next 5Y49.2%
Revenue Next Year12.41%
Revenue Next 2Y14.66%
Revenue Next 3Y26.37%
Revenue Next 5Y16.64%

3.3 Evolution

EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. EOLS Valuation Analysis

4.1 Price/Earnings Ratio

  • EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EOLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

  • EOLS's earnings are expected to grow with 86.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.8%
EPS Next 3Y86.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EOLS Dividend Analysis

5.1 Amount

  • No dividends for EOLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EOLS Fundamentals: All Metrics, Ratios and Statistics

EVOLUS INC

NASDAQ:EOLS (3/5/2026, 2:52:01 PM)

5.79

+0.2 (+3.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-05
Inst Owners80.28%
Inst Owner Change-9.75%
Ins Owners9.06%
Ins Owner Change7.03%
Market Cap375.31M
Revenue(TTM)N/A
Net Income(TTM)-58.56M
Analysts84.62
Price Target14.96 (158.38%)
Short Float %14.57%
Short Ratio7.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.65%
Min EPS beat(2)-108.79%
Max EPS beat(2)37.48%
EPS beat(4)2
Avg EPS beat(4)-17.26%
Min EPS beat(4)-108.79%
Max EPS beat(4)37.48%
EPS beat(8)4
Avg EPS beat(8)-20.62%
EPS beat(12)8
Avg EPS beat(12)-11.91%
EPS beat(16)10
Avg EPS beat(16)-7.81%
Revenue beat(2)1
Avg Revenue beat(2)-8.42%
Min Revenue beat(2)-17.08%
Max Revenue beat(2)0.25%
Revenue beat(4)1
Avg Revenue beat(4)-6.22%
Min Revenue beat(4)-17.08%
Max Revenue beat(4)0.25%
Revenue beat(8)2
Avg Revenue beat(8)-3.54%
Revenue beat(12)5
Avg Revenue beat(12)-1.7%
Revenue beat(16)6
Avg Revenue beat(16)-1.26%
PT rev (1m)-18.52%
PT rev (3m)-21.43%
EPS NQ rev (1m)-13.04%
EPS NQ rev (3m)-13.04%
EPS NY rev (1m)3.93%
EPS NY rev (3m)9.04%
Revenue NQ rev (1m)-0.99%
Revenue NQ rev (3m)-1.49%
Revenue NY rev (1m)-0.33%
Revenue NY rev (3m)0.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS4.41
BVpS-0.44
TBVpS-1.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.83%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score2
Asset Turnover1.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.54%
Cap/Sales 2.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.53
Altman-Z -2.24
F-Score2
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)67.26%
Cap/Depr(5y)52.74%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y91.3%
EPS Next 2Y63.8%
EPS Next 3Y86.6%
EPS Next 5Y49.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.38%
Revenue Next Year12.41%
Revenue Next 2Y14.66%
Revenue Next 3Y26.37%
Revenue Next 5Y16.64%
EBIT growth 1Y-20.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-616.62%
EBIT Next 3Y231.57%
EBIT Next 5Y178.96%
FCF growth 1Y-25.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.36%
OCF growth 3YN/A
OCF growth 5YN/A

EVOLUS INC / EOLS FAQ

What is the ChartMill fundamental rating of EVOLUS INC (EOLS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to EOLS.


What is the valuation status of EVOLUS INC (EOLS) stock?

ChartMill assigns a valuation rating of 1 / 10 to EVOLUS INC (EOLS). This can be considered as Overvalued.


How profitable is EVOLUS INC (EOLS) stock?

EVOLUS INC (EOLS) has a profitability rating of 1 / 10.


What is the financial health of EVOLUS INC (EOLS) stock?

The financial health rating of EVOLUS INC (EOLS) is 2 / 10.


Can you provide the expected EPS growth for EOLS stock?

The Earnings per Share (EPS) of EVOLUS INC (EOLS) is expected to grow by 91.3% in the next year.